Prescription Drug Pricing
House Bill 624 would create a new Article 4D in Chapter 90 of the North Carolina General Statutes to increase transparency around prescription drug pricing. The bill requires drug manufacturers to give advance notice to specified “interested parties” — including state agencies, insurers, health care service plan providers, and pharmacy benefits managers — before a substantial price increase, defined as a 10% or greater increase over 12 months. It also requires disclosure of supporting information such as a justification for the increase, prior marketing budgets, acquisition price and date if applicable, and the drug’s price history over the previous five years.
The bill also imposes disclosure requirements for new prescription drugs shortly after FDA approval, including the drug’s price and related pricing justification and marketing budget information. In addition, if a manufacturer or its agent markets a drug to a prescriber, it must disclose whether any ingredient is known to pose a risk of dependency in humans. The Secretary of Health and Human Services would be responsible for assessing civil penalties for noncompliance, developing a data-collection implementation plan, creating a public online portal for disclosures, and issuing annual reports on the most frequently prescribed, most costly, and fastest-rising prescription drugs in the state. The act would take effect October 1, 2025, and it expressly states that it does not limit a manufacturer’s ability to charge any lawful price.
If enacted, the bill would add a new transparency framework to North Carolina’s drug-pricing laws without directly regulating or capping prices. It would expand the Department of Health and Human Services’ role in collecting and publishing prescription drug pricing data, create new reporting obligations for manufacturers, and authorize civil penalties of up to $1,000 per day for failures to report. The bill would affect manufacturers, insurers, PBMs, state purchasers, prescribers, and the public through required disclosures and a public portal, while also directing annual reporting to legislative oversight committees.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears policy-driven and reform-oriented rather than overtly partisan. The bill’s stated purpose is to promote transparency and accountability in prescription drug pricing, suggesting support for consumer-facing disclosure measures and oversight of drug costs. No formal vote history or transcript comments are available here to indicate opposition or amendments.
The main likely point of contention is the burden the bill places on pharmaceutical manufacturers, who would have to provide advance notice and detailed pricing-related disclosures, including information that may be commercially sensitive. Another possible issue is whether the state should collect and publish this data, given administrative costs and concerns about confidentiality or trade secrets. At the same time, the bill explicitly avoids price controls, which may reduce opposition from those concerned about direct regulation, but it may also lead critics to question whether transparency alone will meaningfully affect drug affordability.